Literature DB >> 11942961

Does site-specific labelling and individual processing of sextant biopsies improve the accuracy of prostate biopsy in predicting pathological stage in patients with T1c prostate cancer?

B Tombal1, N Tajeddine, J-P Cosyns, A Feyaerts, R Opsomer, F X Wese, P J Van Cangh.   

Abstract

OBJECTIVE: To evaluate whether individual labelling and processing of the sextant of origin improves the accuracy of prostate biopsy in predicting the final pathological stage after radical prostatectomy in patients with T1c prostate cancer. PATIENTS AND METHODS: The charts of 386 patients treated for prostate cancer by radical prostatectomy between January 1996 and June 1999 were reviewed. In all, 124 patients fulfilled the following inclusion criteria: no abnormality on digital rectal examination (DRE) or transrectal ultrasonography, a prostate specific antigen (PSA) level before biopsy of < or = 20 ng/mL, and prostate cancer diagnosed after one set of random sextant biopsies, with the cores being submitted in six separate containers individually labelled for the sextant of origin.
RESULTS: Within this series of patients with a low tumour burden, the preoperative PSA, biopsy Gleason score and unilateral vs bilateral involvement were not significant predictors of disease extension. The percentage of positive cores and the number and topography of positive sextants were both statistically significant predictors of organ-confined disease. Although these two variables appeared to be statistically equivalent on a first analysis in the overall series, a subgroup of patients was identified who benefited from the complete topographical information, i.e. those 52 (42%) patients with a Gleason score of < 7, 25-75% positive biopsies and < or =3 positive sextants.
CONCLUSION: These results support the individual labelling of biopsy cores in selected patients with a normal DRE and a moderately elevated PSA, as it helps to better predict the final pathological stage. This substantial benefit outweighs the additional effort by the pathologist.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11942961     DOI: 10.1046/j.1464-410x.2002.02672.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

Review 1.  Standards for prostate biopsy.

Authors:  Marc A Bjurlin; Samir S Taneja
Journal:  Curr Opin Urol       Date:  2014-03       Impact factor: 2.309

2.  Is quadrant biopsy sufficient in men likely to have advanced prostate cancer? Comparison with extended biopsy.

Authors:  Zoran Brnic; Slavko Gasparov; Petar Vladislav Lozo; Petar Anic; Leonardo Patrlj; Vesna Ramljak
Journal:  Pathol Oncol Res       Date:  2005-03-31       Impact factor: 3.201

Review 3.  Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing.

Authors:  Marc A Bjurlin; H Ballentine Carter; Paul Schellhammer; Michael S Cookson; Leonard G Gomella; Dean Troyer; Thomas M Wheeler; Steven Schlossberg; David F Penson; Samir S Taneja
Journal:  J Urol       Date:  2013-02-26       Impact factor: 7.450

4.  Specimen orientation by marking the peripheral end: (potential) clinical advantages in prostate biopsy.

Authors:  Andrea Benedetto Galosi; Giovanni Muzzonigro; Vito Lacetera; Roberta Mazzucchelli
Journal:  Prostate Cancer       Date:  2011-07-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.